It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Super-enhancers regulate genes with important functions in processes that are cell type-specific or define cell identity. Mouse embryonic fibroblasts establish 40 senescence-associated super-enhancers regardless of how they become senescent, with 50 activated genes located in the vicinity of these enhancers. Here we show, through gene knockdown and analysis of three core biological properties of senescent cells that a relatively large number of senescence-associated super-enhancer-regulated genes promote survival of senescent mouse embryonic fibroblasts. Of these, Mdm2, Rnase4, and Ang act by suppressing p53-mediated apoptosis through various mechanisms that are also engaged in response to DNA damage. MDM2 and RNASE4 transcription is also elevated in human senescent fibroblasts to restrain p53 and promote survival. These insights identify key survival mechanisms of senescent cells and provide molecular entry points for the development of targeted therapeutics that eliminate senescent cells at sites of pathology.
To develop therapeutics that selectively eliminate pathological senescent cells it is important to understand their survival mechanisms. Here, the authors show that senescent cells manage to survive by keeping p53 activity in check through multiple mechanisms, including inhibitory mechanisms that involve p53 binding to ribonucleases.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 Mayo Clinic, Department of Pediatric and Adolescent Medicine, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X); University of Groningen, University Medical Center Groningen, Department of Pediatrics, Molecular Genetics Section, Groningen, The Netherlands (GRID:grid.4494.d) (ISNI:0000 0000 9558 4598)
2 Mayo Clinic, Department of Pediatric and Adolescent Medicine, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X)
3 Mayo Clinic, Department of Molecular Pharmacology and Experimental Therapeutics, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X)
4 Mayo Clinic, Department of Pediatric and Adolescent Medicine, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X); Mayo Clinic, Department of Biochemistry and Molecular Biology, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X)